Latest & greatest articles for sertraline

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sertraline or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sertraline and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sertraline

1. Efficacy of sertraline for post stroke depression (PSD): a systematic review protocol of randomized controlled trials

Efficacy of sertraline for post stroke depression (PSD): a systematic review protocol of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

2. Effects of sertraline in the prevention of low blood pressure in patients undergoing hemodialysis. (PubMed)

Effects of sertraline in the prevention of low blood pressure in patients undergoing hemodialysis. Intradialytic hypotension (IDH) is a major complication of hemodialysis, with a prevalence of about 25% during hemodialysis sessions, causing increased morbidity and mortality.To study the effects of sertraline to prevent IDH in hemodialysis patients.This was a double-blind, crossover clinical trial comparing the use of sertraline versus placebo to reduce intradialytic hypotension.Sixteen patients (...) completed the two phases of the study during a 12-week period. The IDH prevalence was 32%. A comparison between intradialytic interventions, intradialytic symptoms, and IDH episodes revealed no statistical difference in the reduction of IDH episodes (p = 0.207) between the two intervention groups. However, the risk of IDH interventions was 60% higher in the placebo group compared to the sertraline group, and the risk of IDH symptoms was 40% higher in the placebo group compared to the sertraline group

2019 Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia Controlled trial quality: uncertain

3. Doubly Randomized Preference Trial of Prolonged Exposure Versus Sertraline for Treatment of PTSD

Doubly Randomized Preference Trial of Prolonged Exposure Versus Sertraline for Treatment of PTSD The authors examined the effect of patient treatment preference on the differential effectiveness of prolonged exposure and sertraline for the treatment of posttraumatic stress disorder (PTSD).In a doubly randomized preference trial, 200 patients with PTSD viewed standardized treatment rationales prior to randomization. Patients were first randomized to choice of treatment or no choice. Those (...) assigned to no choice were then randomized to prolonged exposure or sertraline. Acute treatment was 10 weeks, with 24-month follow-up. Interviewer-rated PTSD symptom severity was the main outcome measure, and depression, anxiety, and functioning were assessed as additional outcomes.Patients preferred prolonged exposure over sertraline (number needed to benefit [NNTB]=4.5). Using intent-to-treat analyses (N=200), both prolonged exposure and sertraline showed large gains that were maintained over 24

2018 EvidenceUpdates

4. Sertraline

Sertraline Top results for sertraline - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for sertraline The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

5. Bilateral cystoid macular edema misdiagnosed as pars planitis in a patient on sertraline therapy (PubMed)

Bilateral cystoid macular edema misdiagnosed as pars planitis in a patient on sertraline therapy To describe the presentation, clinical course and management of a patient with bilateral maculopathy associated with sertraline.We report a rare case of bilateral cystoid macular edema and subretinal fluid in a 78-year-old Asian Indian female who was on chronic sertraline therapy. The patient was initially misdiagnosed as intermediate uveitis and started on oral corticosteroids. However, multimodal (...) imaging with fluorescein angiography and optical coherence tomography ruled out ocular inflammation. There was symmetrical bilateral macular involvement and changes on macular electroretinography, which provided clues to the diagnosis of toxic maculopathy. After cessation of sertraline therapy, the retinal pathology reversed with improvement in visual acuity.Development of cystoid macular edema due to sertraline is a very rare adverse event and must be considered by psychiatrists and ophthalmologists

Full Text available with Trip Pro

2018 American journal of ophthalmology case reports

6. The effects of combined sertraline and aspirin therapy on depression severity among patients with major depressive disorder: A randomized clinical trial (PubMed)

The effects of combined sertraline and aspirin therapy on depression severity among patients with major depressive disorder: A randomized clinical trial Different studies have been conducted to find the best adjuvant therapies for depression management. There are controversies over the effects of aspirin as an adjuvant therapy for depression.To determine the effects of combined sertraline and aspirin therapy on depression severity among patients with major depressive disorder.This randomized (...) clinical trial was conducted at Kargarnejad Psychiatric Hospital in Kashan, Isfahan, Iran, from September 1, 2016 to November 1, 2016. The study participants included 100 patients with major depressive disorder who were assigned to aspirin and placebo groups by the use of computer-generated random numbers. Patients in these groups respectively received sertraline-aspirin and sertraline-placebo for eight consecutive weeks. Patients were prescribed 80 milligrams of aspirin twice a day. Also, sertraline

Full Text available with Trip Pro

2017 Electronic physician Controlled trial quality: uncertain

7. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. (PubMed)

Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. Major depressive disorder (MDD) is prevalent among patients with chronic kidney disease (CKD) and is associated with morbidity and mortality. The efficacy and adverse events of selective serotonin reuptake inhibitors in these patients are unknown.To determine whether treatment with sertraline improves depressive symptoms in patients with CKD (...) and MDD.The Chronic Kidney Disease Antidepressant Sertraline Trial (CAST) was a randomized, double-blind, placebo-controlled trial involving 201 patients with stage 3, 4, or 5 non-dialysis-dependent CKD, who were enrolled at 3 US medical centers. The Mini Neuropsychiatric Interview was used to establish MDD. The first participant was randomized in March 2010 and the last clinic visit occurred in November 2016.After a 1-week placebo run-in, participants were randomized to sertraline (n = 102) for 12 weeks

Full Text available with Trip Pro

2017 JAMA Controlled trial quality: predicted high

8. Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity psychological

Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity psychological Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity (...) psychological treatments as defined by the National Institute for Health and Care Excellence guidelines Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity psychological treatments as defined by the National Institute for Health and Care Excellence guidelines Buszewicz M, Cape J, Serfaty M, Shafran R, Kabir T, Tyrer P

2017 Health Technology Assessment (HTA) Database.

9. Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity psychological

Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity psychological Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity

2017 NIHR HTA programme

10. Sertraline for Preventing Mood Disorders Following Traumatic Brain Injury: A Randomized Clinical Trial.

Sertraline for Preventing Mood Disorders Following Traumatic Brain Injury: A Randomized Clinical Trial. Prevention is more effective than treatment to decrease the burden of significant medical conditions such as depressive disorders, a major cause of disability worldwide. Traumatic brain injury (TBI) is a candidate for selective strategies to prevent depression given the incidence, prevalence, and functional effect of depression that occurs after TBI.To assess the efficacy of sertraline (...) treatment in preventing depressive disorders following TBI.A double-blind, placebo-controlled, parallel-group randomized clinical trial was conducted at a university hospital from July 3, 2008, to September 17, 2012, with 24 weeks of follow-up. A consecutive sample of 534 patients aged 18 to 85 years, hospitalized for mild, moderate, or severe TBI, was eligible for the study. Ninety-four patients consented to participate and were randomized (46 to placebo and 48 to sertraline), of whom 79 (84

Full Text available with Trip Pro

2016 EvidenceUpdates

11. Pharmacological interventions: Are sertraline, paroxetine and duloxetine the most effective antidepressants for use in depressed adults over 60?years?

Pharmacological interventions: Are sertraline, paroxetine and duloxetine the most effective antidepressants for use in depressed adults over 60?years? Are sertraline, paroxetine and duloxetine the most effective antidepressants for use in depressed adults over 60 years? | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Are sertraline, paroxetine and duloxetine the most effective antidepressants for use in depressed adults over 60

2016 Evidence-Based Mental Health

12. Sertraline use during pregnancy and the risk of major malformations (PubMed)

Sertraline use during pregnancy and the risk of major malformations Given the current debate and growing public concerns on selective serotonin reuptake inhibitors (SSRIs) and birth defects generated by Food and Drug Administration warnings, we aim to quantify the association between first-trimester exposure to sertraline, a first-line treatment, and the risk of congenital malformations in a cohort of depressed women.This was a population-based cohort study in Quebec, Canada, 1998 through 2010 (...) . From a cohort of 18,493 depressed/anxious pregnancies, sertraline-exposed, nonsertraline SSRI-exposed, non-SSRI exposed, and unexposed (reference category) women were studied. Major malformations overall and organ-specific malformations in the first year of life were identified. Generalized estimating equation models were used to obtain risk estimates and 95% confidence intervals (CIs). Analyses were adjusted for potential confounders.Among the 18,493 eligible pregnancies, 366 were exposed

2015 EvidenceUpdates

13. Sertraline

Sertraline USE OF SERTRALINE IN PREGNANCY 0344 892 0909 USE OF SERTRALINE IN PREGNANCY (Date of issue: January 2017 , Version: 2.2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Sertraline is a selective serotonin reuptake inhibitor (SSRI) used (...) in the treatment of depression, obsessive-compulsive disorder, post-traumatic stress disorder, social anxiety disorder and panic disorder with or without agoraphobia. Data on the risk of congenital malformations following sertraline use in early pregnancy are conflicting. The majority of individual studies and two meta-analyses demonstrate no statistically significant increase in the overall risk of any malformation or of cardiovascular malformations following first trimester exposure. However, four individual

2014 UK Teratology Information Service

14. Longer term outcomes need to be examined for enhancing the treatment of social anxiety disorder after insufficient improvement with sertraline

Longer term outcomes need to be examined for enhancing the treatment of social anxiety disorder after insufficient improvement with sertraline Longer term outcomes need to be examined for enhancing the treatment of social anxiety disorder after insufficient improvement with sertraline | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we (...) insufficient improvement with sertraline Article Text Pharmacological interventions Longer term outcomes need to be examined for enhancing the treatment of social anxiety disorder after insufficient improvement with sertraline Kristy L Dalrymple Statistics from Altmetric.com What is already known on this topic? Despite the efficacy of treatments for social anxiety disorder (SAD), a percentage of patients do not respond to initial treatment or continue to experience residual symptoms. Given the significant

2014 Evidence-Based Mental Health

15. Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial

Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial Romeo R, Knapp M, Hellier J, Dewey M, Ballard C, Baldwin R, Bentham P, Burns A, Fox C, Holmes C, Katona C, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, O'Brien J (...) , Poppe M, Thomas A, Walwyn R, Wilson K, Banerjee S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of sertraline and mirtazapine, for the treatment of depression, in patients

Full Text available with Trip Pro

2013 NHS Economic Evaluation Database.

16. The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial (PubMed)

The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial Transcranial direct current stimulation (tDCS) trials for major depressive disorder (MDD) have shown positive but mixed results.To assess the combined safety and efficacy of tDCS vs a common pharmacological treatment (sertraline hydrochloride, 50 mg/d).Double-blind, controlled trial. Participants were randomized using a 2 × 2 factorial design to sertraline (...) /placebo and active/sham tDCS.Outpatient, single-center academic setting in São Paulo, Brazil.One hundred twenty antidepressant-free patients with moderate to severe, nonpsychotic, unipolar MDD.Six-week treatment of 2-mA anodal left/cathodal right prefrontal tDCS (twelve 30-minute sessions: 10 consecutive sessions once daily from Monday to Friday plus 2 extra sessions every other week) and sertraline hydrochloride (50 mg/d). MAIN OUTCOME MEASURES In this intention-to-treat analysis, the primary outcome

Full Text available with Trip Pro

2013 EvidenceUpdates Controlled trial quality: predicted high

17. Study of the use of antidepressants for depression in dementia: the HTA -SADD trial - a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine

Study of the use of antidepressants for depression in dementia: the HTA -SADD trial - a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine Study of the use of antidepressants for depression in dementia: the HTA -SADD trial - a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine Journals Library An error has

2013 NIHR HTA programme

18. Sertraline effective for acute major depression

Sertraline effective for acute major depression PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They are funded by the New Zealand Guidelines Group. PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement in the management of individual cases. View PEARLS online at: www.cochraneprimarycare.org (...) Sertraline effective for acute major depression Clinical question How effective is sertraline (escitalopram) in the acute phase treatment of major depression? Bottom line There was evidence favouring sertraline over some other antidepressants for the acute phase treatment of major depression, in terms of efficacy, compared with fluoxetine, (NNT* 10; range, 6 to 14) or acceptability/tolerability, compared with amitriptyline, imipramine, paroxetine and mirtazapine. Follow-up was limited to 24 weeks

2012 Cochrane PEARLS

19. Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression

Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression Article Text Aetiology Fluoxetine

2012 Evidence-Based Mental Health

20. Sertraline and mirtazapine do not reduce severity of depression in people with dementia

Sertraline and mirtazapine do not reduce severity of depression in people with dementia Sertraline and mirtazapine do not reduce severity of depression in people with dementia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Sertraline and mirtazapine do not reduce severity of depression in people with dementia Article Text Therapeutics Sertraline and mirtazapine do not reduce severity of depression in people with dementia Statistics from

2012 Evidence-Based Mental Health